The atherosclerosis market is anticipated to attain a valuation of USD 59,514.3 million by 2033, capturing a CAGR of 2.8% between 2023 and 2033 from a current value of USD 45,165.6 million in 2023. The rise in the prevalence of cardiovascular disorders is a significant factor driving market growth.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 45,165.6 million |
| Anticipated Forecast Value (2033) | USD 59,514.3 million |
| Projected Growth Rate (2023 to 2033) | 2.8% CAGR |
Atherosclerosis is the shrinking of a vein caused by plaque accumulation. Atherosclerosis is a kind of arteriosclerosis (stiffening or solidifying of the artery walls). The sickness disrupts the flow of blood throughout the body, posing significant cardiovascular complications.
Atherosclerosis starts when the endothelium is damaged, allowing LDL cholesterol to accumulate in the arterial wall. To clean up the cholesterol, the body sends macrophage white platelets.
However, the cells occasionally halt at the impacted spot. After a while, this resulted in plaque formation, which was composed of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, disrupting the flow of blood throughout the body. This may result in blood clusters, which can lead to life-threatening diseases such as heart attack, stroke, and other cardiovascular disorders.
Aside from age, the following factors increase the risk of atherosclerosis: high blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and a poor diet.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for atherosclerosis treatment is projected to increase at a CAGR of 2.8% during the forecast period between 2023 and 2033, reaching a total of USD 59,514.3 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.8%.
The rise in heart attacks caused by atherosclerosis or coronary heart disease is expected to drive up demand for atherosclerosis treatment products. The aging population is expected to drive demand during the forecast period.
According to the CDC (Centres for Disease Control and Prevention), coronary illness accounts for approximately 610,000 deaths per year in the United States, accounting for roughly one out of every four reported deaths. Coronary disease is the most well-known type of coronary disease, killing over 370,000 people each year.
This increase in the baby boomer population is expected to increase in atherosclerosis patients and, as a result, demand for treatment over the forecast period.
The market for atherosclerosis is growing due to increased prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, particularly a decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down.
Statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs), and nitrates are among the medications used to treat atherosclerosis.
Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are expected to be launched during the forecasting period.
An Expanding Geriatric Population Base and Subsequent Rise in Cardiac Anomalies
The worldwide atherosclerosis industry is poised to increase as the geriatric population grows and the incidence rate of heart attacks caused by coronary heart disease or atherosclerosis rises. Furthermore, the availability of new treatment approaches (both branded and generic) is a key driver of the global atherosclerosis therapeutics market.
According to the Centres for Disease Control and Prevention (CDC), approximately 610 000 people in the United States died as a result of heart disease, accounting for nearly one out of every four deaths. Coronary artery disease is the most common type of heart disease, accounting for around 370,000 deaths each year. These factors are expected to boost the global market for atherosclerosis.
Increasing Prevalence of Obesity and High Cholesterol to Widen Growth Prospects
Rising obesity and high cholesterol rates are expected to boost market growth by increasing the risk of atherosclerosis. According to the World Health Organization, around 40 million children under five were overweight or obese in 2018. (WHO).
Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, all contribute to high cholesterol rates, resulting in rapid market growth.
Furthermore, rising awareness-raising initiatives by public and private organizations are expected to expand the atherosclerosis market. Furthermore, the sedentary lifestyle of people, such as high alcohol consumption and smoking addiction, is projected to result in the expansion of the atherosclerosis market. The rising level of disposable income and the high prevalence of high blood pressure are expected to drive the industry's growth rate during the forecast period.
Principal Consultant
Absence of Definitive Therapy to Stymie the Market Growth
New competitors in the atherosclerosis market have demonstrated increased adequacy and security profiles, as well as a reduction in CHD risk factors. Atherosclerosis, also known as coronary artery disease, has two treatment options: coronary artery bypass grafting (CABG) and angioplasty.
The CAD death rate is relatively high when compared to other diseases caused by coronary events associated with CAD, such as myocardial infections (MI), angina, and strokes. As a result, the antidote to such situations remains an unexplored area of research and development for pharmaceutical companies seeking to bring breakthrough drugs to market.
However, the absence of definitive therapy, side effects and limited efficacy of current medications, and reliance on symptom-based treatment in certain situations are likely to hinder revenue growth in the atherosclerosis market throughout the forecast period.
Moreover, the high cost of the treatment is expected to hamper the market's growth rate. The atherosclerosis market is estimated to be challenged by a lack of skilled professionals and a dearth of healthcare infrastructure in developing economies. Furthermore, strict regulatory policies and a lack of public awareness might restrain and impede market growth during the forecast period.
High Prevalence of Cardiovascular Diseases Creating Opportunities for Atherosclerosis Treatment Providers
| Country | Forecast CAGR % (2023 to 2033) |
|---|---|
| North America’s Market Share % (2022) | 37.8% |
| The United States Market Share % (2022) | 32.4% |
The North American atherosclerosis market is slated to acquire a market share of 37.8% in 2022. The presence of key players, the high prevalence of cardiovascular diseases and atherosclerosis, and the established healthcare infrastructure are some key factors responsible for the market's large share. Furthermore, beneficial government initiatives and an increase in the number of research collaborations are expected to drive market growth.
Because of supportive healthcare policies, several patients, and a developed healthcare market, the United States have the largest share in this region. Around 647,000 Americans die annually from heart disease, accounting for one in every four deaths.
Every year, the United States spends around USD 219 billion on heart disease. According to statistics, this country's increasing patient pool and disposable revenue drive regional market growth.
Increasing Geriatric Population Favoring Market Growth
| Country | Forecast CAGR % (2023 to 2033) |
|---|---|
| China | 3.9% |
| India | 4.4% |
The Asia Pacific is anticipated to increase during the forecast period due to an increasing geriatric population and rising disposable income levels in this region.
Furthermore, the expansion of healthcare infrastructure and rising government initiatives are expected to accelerate the market's growth rate in this region. Thus, the Asia Pacific is expected to hold 25% of the market share for the atherosclerosis market in the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cholesterol-lowering Medications to Remain Most Sought After
| Segment | Market Share % (2022) |
|---|---|
| Cholesterol Lowering Medication | 44.7% |
Statins and fibrates are examples of cholesterol-lowering medications. The segment's dominance is attributed to the rising prevalence of cardiovascular disease, high cholesterol, and obesity worldwide. According to the World Health Organization, 40 million children under the age of five were overweight or obese in 2018.
A higher intake of energy-dense foods high in fat and sugars, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, are factors driving high cholesterol rates and, ultimately, boosting segment growth.
In addition, the approval of new cholesterol-lowering medicines is boosting segment growth. For example, the drugs alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs known as PCSK9 inhibitors, which reduce harmful LDL cholesterol levels by more than 50%. Novel treatment drugs of this type boost segment growth. The growing patient pool and increased approvals for new medicines boost segment growth.
Retail Pharmacies are expected to Continue to Be a Beneficial Distribution Channel
| Segment | Market Share % (2022) |
|---|---|
| Retail Pharmacies | 38.2% |
As per Future Market Insights (FMI), the retail pharmacies segment is expected to become the primary point-of-sale channel for atherosclerosis as they expand to even the most remote locations, making it easier for consumers to present prescriptions and purchase drugs.
Furthermore, retail pharmacists provide more consultative services regarding drug administration routes and potential side effects. Retail pharmacies carry a variety of brands, making them a good place for patients to shop. Hospital pharmacists, on the other hand, operate in a more clinic-oriented manner, having frequent contact with doctors and nurses, and they manage their inventories with only specific brands.
Key startup players in the atherosclerosis market:
The market for atherosclerosis is moderately competitive, with several key players. Some companies that are currently dominating the market are as follows GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics are some prominent players.
Recent Developments in the Atherosclerosis Market Are
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 45,165.6 million |
| Market Value in 2033 | USD 59,514.3 million |
| Growth Rate | CAGR of 2.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Therapy, Surgery, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; The Middle East and Africa |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, GCC, South Africa, Israel |
| Key Companies Profiled | GlaxoSmithKline plc.; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.; Isis Pharmaceuticals, Inc.; Anthera Pharmaceuticals; Novartis AG; Sanofi; Johnson and Johnson; Bayer AG; The Medicine Company; Cardium Therapeutics |
| Customization | Available Upon Request |
An increasing geriatric population drives the Asia Pacific market.
The increasing prevalence of obesity and high cholesterol drives sales.
The United States expanded at a CAGR of 32.4% in 2022.
The high prevalence of cardiovascular diseases and atherosclerosis in North America offers growth opportunities.
India expanded at a CAGR of 4.4% in 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 5.1. Atherosclerosis Medications 5.2. Cholesterol-lowering Medications 5.3. Antiplatelet Drugs and Anticoagulants 5.4. Atherosclerosis Beta Blockers 5.5. Diuretics or Water Pills 5.6. Angiotensin Converting Enzyme (ACE) Inhibitors 5.7. Others 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Surgery 6.1. Bypass Surgery (Coronary Artery Bypass Grafting (CABG)) 6.2. Angioplasty 6.3. Atherectomy 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospitals 7.2. Pharmacies 7.3. Drug Stores 7.4. Retail Pharmacies 7.5. Clinics 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. GlaxoSmithKline plc. 18.2. Merck & Co., Inc. 18.3. F. Hoffmann-La Roche Ltd. 18.4. Isis Pharmaceuticals, Inc. 18.5. Anthera Pharmaceuticals 18.6. Novartis AG 18.7. Sanofi 18.8. Johnson and Johnson 18.9. Bayer AG 18.10. The Medicine Company 18.11. Cardium Therapeutics 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Atherosclerosis Market
